Abionyx Pharma's Stock Plummets 8.5% Following Capital Increase

Stock Plunges 8.56% to €2.35 After Successful €18.7 Million Capital Raise

Abionyx Pharma's stock loses 8.56% at €2.35 mid-morning, while the CAC 40 is up 0.45% and the SBF 120 advances by 0.39%. The French biopharmaceutical company announced this Thursday the successful completion of its capital increase of 18.7 million euros, accompanied by the submission of a notice of drawdown for a first tranche of 10 million euros in bonds with Danish fund Fenja Capital. The operation, which had a subscription price set at €2.65 per share at its launch on May 27, aims to finance clinical programs in sepsis and regulatory advancements in LCAT deficiency.

The current price is now 11% below this subscription price, reflecting the market-integrated dilution. The stock is among the steepest declines in the CAC All Shares this morning, even as the overall dynamics of the Parisian market are positive.

A Decline that Extends a Fundamental Slide and Breaks Key Support at €2.54

The previous session had already seen the stock break its support at €2.54, dropping to a low of €2.51, before closing above at €2.57. Thursday's movement confirms the break, with the price firmly settling below this technical threshold. The situation remains degraded: the stock is trading 18.69% below its MM20 (€2.89) and more than 34% below its MM200 (€3.60), while the RSI drops to 25, into a marked oversold zone.

Over three months, the decline reaches 29.44%, while the performance over one year remains positive (+90.28%), a remnant of the late 2025 rally. The loss of 12.38% over the week reflects the acceleration of the decline; the company had announced the financing operation at the end of May. With the price now distant from all its moving averages and a broken reference support, the next observation zone is around the recent lows of €2.51.